Praxis Precision Medicines (PRAX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
10 Jun, 2026Opening remarks and agenda
Meeting commenced with introductions of board members and executive officers joining virtually.
Independent auditors from Ernst & Young LLP were introduced as present.
Agenda and rules of conduct were made available in the virtual portal, with instructions for voting and Q&A.
Board and executive committee updates
Board members and executive officers were introduced, including the CEO, CFO, COO, General Counsel, and SVP of Finance.
Shareholder proposals
Three proposals were presented: election of Class III directors, ratification of auditors, and advisory approval of executive compensation.
No advance notice of director nominations was received from shareholders.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Praxis Precision Medicines
- $1.4B cash, late-stage FDA reviews, and commercial readiness drive 2027 launch plans.PRAX
Q2 2026 - Four CNS therapies with blockbuster potential target >$20B peak sales by 2028.PRAXCorporate presentation
- Pivotal epilepsy studies and a robust pipeline set up multiple clinical catalysts through early 2026.PRAXJefferies Global Healthcare Conference 2025
- Accelerated clinical and regulatory strategies are driving earlier market entry for key therapies.PRAXFireside Chat
- Ulixacaltamide targets a vast unmet need in essential tremor, with a major launch imminent.PRAXGoldman Sachs 47th Annual Global Healthcare Conference 2026
- Ulyxa and relumitragene advance toward launch with strong FDA continuity and broad commercialization plans.PRAXTD Cowen 46th Annual Health Care Conference
- Two NDAs filed, strong clinical data, and $1.5B cash position support 2026 launches.PRAXQ4 2025
- Q3 net loss was $51.9M; $411.2M cash funds late-stage CNS trials into 2027 with key data in 2025.PRAXQ3 2024
- Multiple late-stage clinical readouts and $433.8M cash support operations into 2027.PRAXQ2 2024